CN105209029A - 帕金森病的治疗方法 - Google Patents

帕金森病的治疗方法 Download PDF

Info

Publication number
CN105209029A
CN105209029A CN201480027268.2A CN201480027268A CN105209029A CN 105209029 A CN105209029 A CN 105209029A CN 201480027268 A CN201480027268 A CN 201480027268A CN 105209029 A CN105209029 A CN 105209029A
Authority
CN
China
Prior art keywords
levodopa
weight
carbidopa
arginine
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480027268.2A
Other languages
English (en)
Chinese (zh)
Inventor
奥伦·亚柯比-泽维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuroderm Ltd
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50513395&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105209029(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Priority to CN201911315631.1A priority Critical patent/CN110935026A/zh
Publication of CN105209029A publication Critical patent/CN105209029A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201480027268.2A 2013-03-13 2014-03-13 帕金森病的治疗方法 Pending CN105209029A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911315631.1A CN110935026A (zh) 2013-03-13 2014-03-13 帕金森病的治疗方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779357P 2013-03-13 2013-03-13
US61/779,357 2013-03-13
PCT/IL2014/050261 WO2014141261A1 (en) 2013-03-13 2014-03-13 Method for treatment of parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201911315631.1A Division CN110935026A (zh) 2013-03-13 2014-03-13 帕金森病的治疗方法

Publications (1)

Publication Number Publication Date
CN105209029A true CN105209029A (zh) 2015-12-30

Family

ID=50513395

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911315631.1A Pending CN110935026A (zh) 2013-03-13 2014-03-13 帕金森病的治疗方法
CN201480027268.2A Pending CN105209029A (zh) 2013-03-13 2014-03-13 帕金森病的治疗方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911315631.1A Pending CN110935026A (zh) 2013-03-13 2014-03-13 帕金森病的治疗方法

Country Status (21)

Country Link
US (4) US20160022573A1 (enExample)
EP (2) EP2968218B1 (enExample)
JP (2) JP6472391B2 (enExample)
KR (1) KR102209353B1 (enExample)
CN (2) CN110935026A (enExample)
AU (1) AU2014229127B2 (enExample)
BR (1) BR112015022390A8 (enExample)
CA (1) CA2904838C (enExample)
CL (1) CL2015002641A1 (enExample)
DK (1) DK2968218T3 (enExample)
ES (1) ES2889626T3 (enExample)
HR (1) HRP20211442T1 (enExample)
HU (1) HUE056006T2 (enExample)
IL (1) IL266648B (enExample)
MX (1) MX365206B (enExample)
PL (1) PL2968218T3 (enExample)
PT (1) PT2968218T (enExample)
RU (2) RU2677278C2 (enExample)
SG (2) SG11201507538UA (enExample)
WO (1) WO2014141261A1 (enExample)
ZA (1) ZA201507621B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106413754A (zh) * 2014-03-13 2017-02-15 纽罗德姆有限公司 多巴脱羧酶抑制剂组合物
CN111701024A (zh) * 2020-05-26 2020-09-25 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193243B2 (en) 2009-05-19 2012-06-05 Neuroderm, Ltd. Continuous administration of dopa decarboxylase inhibitors and compositions for same
JP5902705B2 (ja) 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
TR201808178T4 (tr) 2010-11-15 2018-07-23 Neuroderm Ltd Aktif ajanların transdermal dağıtımı için bileşimler.
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3188725B1 (en) 2014-09-04 2020-10-28 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
MX381069B (es) 2014-10-21 2025-03-12 Abbvie Inc Profármacos de carbidopa y l-dopa y métodos de uso.
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
WO2017039525A1 (en) * 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
AU2018280745B2 (en) * 2017-06-05 2023-03-09 Dizlin Pharmaceuticals Ab Levodopa infusion solution
WO2019097120A1 (en) * 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
WO2019147934A1 (en) * 2018-01-29 2019-08-01 Sackner Bernstein Jonathan Methods for dopamine modulation in human neurologic diseases
CA3095341A1 (en) * 2018-03-29 2019-10-03 Avion Pharmaceuticals, Llc Levodopa fractionated dose composition and use
SG11202104499RA (en) 2018-11-15 2021-05-28 Abbvie Inc Pharmaceutical formulations for subcutaneous administration
WO2022047298A1 (en) * 2020-08-31 2022-03-03 Purdue Pharma L.P. Compositions and methods for levodopa delivery
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
WO2023282900A1 (en) * 2021-07-08 2023-01-12 Morehouse School Of Medicine Method and system of diagnosing and treating neurodegenerative disease and seizures
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012066538A1 (en) * 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20080187590A1 (en) * 2005-06-08 2008-08-07 Kari Vahervuo Oral Dosage Form
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
US8193243B2 (en) 2009-05-19 2012-06-05 Neuroderm, Ltd. Continuous administration of dopa decarboxylase inhibitors and compositions for same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012066538A1 (en) * 2010-11-15 2012-05-24 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NYHOLM D ET AL: "Levodopa infusion combined with entacapone or tolcapone in Parkinson disease:a pilot trial.", 《EUROPEAN JOURNAL OF NEUROLOGY：THE OFFICIAL JOURNAL OF THE EUROPEAN FEDERATION OF NEUROLOGICAL SOCIETIES》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106413754A (zh) * 2014-03-13 2017-02-15 纽罗德姆有限公司 多巴脱羧酶抑制剂组合物
CN106413754B (zh) * 2014-03-13 2019-11-29 纽罗德姆有限公司 多巴脱羧酶抑制剂组合物
CN111701024A (zh) * 2020-05-26 2020-09-25 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用

Also Published As

Publication number Publication date
US20210093560A1 (en) 2021-04-01
MX2015012561A (es) 2016-06-28
JP6472391B2 (ja) 2019-02-20
US20230047847A1 (en) 2023-02-16
BR112015022390A2 (pt) 2017-07-18
EP2968218B1 (en) 2021-07-07
RU2677278C2 (ru) 2019-01-16
PL2968218T3 (pl) 2022-01-10
PT2968218T (pt) 2021-09-24
HUE056006T2 (hu) 2022-01-28
EP3892266A1 (en) 2021-10-13
EP2968218A1 (en) 2016-01-20
CA2904838A1 (en) 2014-09-18
IL266648A (en) 2019-07-31
KR20150131230A (ko) 2015-11-24
ZA201507621B (en) 2019-04-24
IL266648B (en) 2020-08-31
CN110935026A (zh) 2020-03-31
ES2889626T3 (es) 2022-01-12
WO2014141261A1 (en) 2014-09-18
JP2019070041A (ja) 2019-05-09
SG11201507538UA (en) 2015-10-29
AU2014229127A1 (en) 2015-11-05
SG10201911731YA (en) 2020-02-27
JP6625773B2 (ja) 2019-12-25
US20160022573A1 (en) 2016-01-28
BR112015022390A8 (pt) 2019-11-26
CL2015002641A1 (es) 2016-03-18
AU2014229127B2 (en) 2018-04-05
JP2016512230A (ja) 2016-04-25
KR102209353B1 (ko) 2021-01-29
CA2904838C (en) 2021-03-16
HRP20211442T1 (hr) 2022-02-04
RU2015143112A (ru) 2017-04-20
US20250177292A1 (en) 2025-06-05
MX365206B (es) 2019-05-27
RU2018144700A (ru) 2019-02-18
DK2968218T3 (da) 2021-09-20

Similar Documents

Publication Publication Date Title
CN105209029A (zh) 帕金森病的治疗方法
US20250114315A1 (en) Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
EP3192500B1 (en) Compositions for continuous administration of dopa decarboxylase inhibitors
HK40012262A (zh) L-多巴、多巴脱羧酶抑制剂、儿茶酚-0-甲基转移酶抑制剂及其组合物的连续施用
HK40046868A (en) Compositions for continuous administration of dopa decarboxylase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151230

RJ01 Rejection of invention patent application after publication